Payment overview · 2025
General Payments
$218.08
11 reported records · 8 companies
Healthcare provider profile · identity verified
Katerina Lynn Devore
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DARDANELLE, AR · NPI 1275040511
Verified facts
What the public records show
CMS Open Payments records show Katerina Lynn Devore received $218.08 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 28.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.13 | 28.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $42.91 | 19.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.60 | 11.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.31 | 11.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.90 | 8.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.12 | 6.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.61 | 6.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.50 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $218.08 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $42.91 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.05 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.08 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.60 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.60 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.60 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.31 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 85 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
60 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
85 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 576 | 149 |
| Omeprazole | Omeprazole | 437 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 395 | 71 |
| Gabapentin | Gabapentin | 332 | 73 |
| Lisinopril | Lisinopril | 303 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 261 | 66 |
| Losartan Potassium | Losartan Potassium | 246 | 66 |
| Ezetimibe | Ezetimibe | 209 | 51 |
| Meloxicam | Meloxicam | 203 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 192 | 59 |
| Metformin Hcl | Metformin Hcl | 184 | 48 |
| Mounjaro | Tirzepatide | 177 | 30 |
| Amlodipine Besylate | Amlodipine Besylate | 169 | 49 |
| Montelukast Sodium | Montelukast Sodium | 161 | 38 |
| Alendronate Sodium | Alendronate Sodium | 154 | 45 |
| Allopurinol | Allopurinol | 139 | 28 |
| Furosemide | Furosemide | 130 | 42 |
| Trazodone Hcl | Trazodone Hcl | 127 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 122 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 121 | 30 |
| Glipizide Er | Glipizide | 120 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 116 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 113 | 34 |
| Buspirone Hcl | Buspirone Hcl | 112 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 19 |
| Potassium Chloride | Potassium Chloride | 111 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 26 |
| Sertraline Hcl | Sertraline Hcl | 108 | 29 |
| Tramadol Hcl | Tramadol Hcl | 107 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 23 |
| Clonazepam | Clonazepam | 93 | 18 |
| Atenolol | Atenolol | 92 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 24 |
| Sucralfate | Sucralfate | 90 | 32 |
| Ozempic | Semaglutide | 85 | 20 |
| Celecoxib | Celecoxib | 84 | 24 |
| Warfarin Sodium | Warfarin Sodium | 84 | suppressed |
| Fenofibrate | Fenofibrate | 83 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 82 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 12 |
| Simvastatin | Simvastatin | 80 | 21 |
| Bupropion Xl | Bupropion Hcl | 77 | 18 |
| Famotidine | Famotidine | 74 | 18 |
| Carvedilol | Carvedilol | 73 | 20 |
| Aripiprazole | Aripiprazole | 72 | 13 |
| Eliquis | Apixaban | 71 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 66 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 13 |
| Temazepam | Temazepam | 64 | suppressed |
| Methocarbamol | Methocarbamol | 63 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 13 |
| Linzess | Linaclotide | 60 | 18 |
| Mirtazapine | Mirtazapine | 60 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 59 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 56 | suppressed |
| Pregabalin | Pregabalin | 54 | 11 |
| Azelastine Hcl | Azelastine Hcl | 51 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | suppressed |
| Glipizide | Glipizide | 50 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 17 |
| Risperidone | Risperidone | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 14 |
| Prednisone | Prednisone | 45 | 39 |
| Propranolol Hcl | Propranolol Hcl | 45 | 13 |
| Jardiance | Empagliflozin | 44 | 12 |
| Estradiol | Estradiol | 42 | suppressed |
| Ondansetron Odt | Ondansetron | 40 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 35 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 33 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 35 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 19 |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 21 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 28 | 12 |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Baclofen | Baclofen | 27 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 27 | 26 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 19 |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 19 |
| Breyna | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 18 | 13 |
| Spironolactone | Spironolactone | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 13 |
| Novolin R Flexpen | Insulin Regular, Human | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Tri-Sprintec | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $218.08 · 11 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, Cologuard Collection Kit, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error